therapeutic action: promotion of neuroplasticity

Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial

mycolabadmin

This study tests whether psilocybin (the active compound in magic mushrooms) combined with therapy can help people with severe alcohol addiction reduce drinking. Participants receive either a high or low dose of psilocybin during a guided session as part of a hospital rehabilitation program. The researchers will measure changes in drinking behavior, mood, anxiety, and brain function to determine if this treatment works better than current options.

Read More »

Psychedelics and the Serotonin Hypothesis of Eating Disorders

mycolabadmin

This review explores how psychedelic drugs like psilocybin (found in certain mushrooms) might help treat eating disorders by promoting flexible thinking and breaking rigid eating patterns. The authors summarize evidence from animal studies and early clinical trials showing that psychedelics work differently than traditional antidepressants by triggering brain changes that help people adopt new, healthier behaviors. While results are promising, more research is needed to determine the best doses, patient populations, and long-term safety.

Read More »

Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin Compounds

mycolabadmin

Scientists extracted and analyzed psilocybin and psilocin from Psilocybe cubensis mushrooms to develop a medication for treating mental health disorders like depression and anxiety. Using various analytical techniques, they confirmed the extract contained about 3.26% psilocybin and was safe, pure, and stable. The research shows that creating a psilocybin-based medicine from these mushrooms is feasible and could offer a new treatment option for people struggling with mental health issues.

Read More »
Scroll to Top